Full Text of PDF (671k)
Article in Japanese
Abstract
Original Article
The use experience of crizotinib for anaplastic lymphoma kinase-positive lung cancer in clinical practice
Noriko Yanagitania Fumiyoshi Ohyanagia Katsumi Nakatomia Keita Kudoa Atsushi Horiikea Noriko Motoib Yuichi Ishikawab Takeshi Horaib Makoto Nishioa
aThoracic Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research
bDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research
ABSTRACT
Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, was approved for clinical practice in Japan in March 2012. ALK-positive lung cancer is rare, and few reports describe the use of crizotinib in Japan. Therefore this report describes its use for 12 ALK-positive lung cancer patients in this hospital from March 2012 to July 2012. Their characteristics were as follows: 7 women and 5 men; median age 49; all 12 presented with adenocarcinoma; 6 were nonsmokers and 6 were light smokers. The response rate to crizotinib in 11 of the 12 patients was 81.8%. The major nonhematological toxicity included visual disorders, serum AST/ALT increase, nausea/vomiting, and drug-induced pneumonitis.
KEYWORDS
non-small cell lung cancer (NSCLC) anaplastic lymphoma kinase (ALK)-positive lung cancer crizotinib
Received 21 Nov 2012 ／ Accepted 31 Jan 2013
AJRS, 2(4): 338-342, 2013
Copyright © The Japanese Respiratory Society All Rights Reserved.